UK asked to consider four-in-one 'super jab'
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A new four-in-one jab that combines vaccines for measles, mumps, rubella and chicken pox will be put forward for possible use in Britain.
The new "super jab" has been developed by the drugs company GlaxoSmithKline, which plans to file an application for a European licence later this year.
If approved, the vaccine could be in use as early as 2003 across European Union member states. But a Department of Health spokeswoman said: "We are not in any way considering adding any vaccine to MMR at the moment. If and when such a vaccine is licensed, we will consider all the evidence on its safety and efficacy in combating chickenpox and shingles."
The jab is not yet available anywhere in the world. But the manufacturers could be keen to supply Britain, which has no licensed vaccine for chickenpox, even though there are ongoing concerns over a possible but unproven link between MMR and autism.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments